Evaluation of splenomegaly

Última revisão: 13 Sep 2025
Última atualização: 03 Oct 2025

Resumo

Diagnósticos diferenciais

comuns

  • Alcohol induced
  • Steatotic liver disease
  • Primary biliary cholangitis (PBC)
  • Primary sclerosing cholangitis
  • Hemochromatosis
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma (NHL)
  • Waldenström macroglobulinemia or lymphoplasmacytic lymphoma
  • Acute myeloid leukemia (AML)
  • Chronic myeloid leukemia (CML)
  • Acute lymphoblastic leukemia (ALL)
  • Chronic lymphocytic leukemia (CLL)
  • Hairy cell leukemia
  • Myelofibrosis
  • Polycythemia vera
  • Essential thrombocytosis
  • Splenic metastases
  • Autoimmune hemolytic anemia
  • Rheumatoid arthritis (RA)
  • Felty syndrome
  • Systemic lupus erythematosus
  • Sarcoidosis
  • Malaria
  • Epstein-Barr virus (EBV)
  • Endocarditis
  • Sepsis-related splenic abscesses
  • Chronic hepatitis C
  • Chronic hepatitis B
  • Sickle cell anemia
  • Cytoskeletal defects
  • Thalassemias
Detalhes completos

Incomuns

  • Benign splenic tumors
  • Portal vein thrombosis
  • Splenic vein thrombosis
  • Budd-Chiari syndrome
  • Hemophagocytic lymphohistiocytosis (HLH)
  • Amyloidosis
  • Gaucher or Niemann-Pick disease
  • Severe dengue
  • Splenic rupture
  • Subcapsular hemorrhage
  • Secondary to granulocyte colony-stimulating factor (G-CSF)
Detalhes completos

Colaboradores

Autores

Terri L. Parker, MD

Assistant Professor of Medicine

Section of Hematology

Yale School of Medicine

Smilow Cancer Center at Yale-New Haven

New Haven

CT

Declarações

TLP declares that she has no competing interests.

Agradecimentos

Dr Terri L. Parker would like to gratefully acknowledge Dr Alan E. Lichtin, the previous contributor to this monograph.

Declarações

AEL has received research support from Amgen.

Revisores

Priyanka Mehta, MD

Consultant Haematologist

Bristol Haematology and Oncology Centre

Bristol

UK

Declarações

PM declares that she has no competing interests.

Ruben A. Mesa, MD

Professor of Medicine

Mayo Clinic

Scottsdale

AZ

Declarações

RAM declares that he has no competing interests.

Giovanni Barosi, MD

Director of the Laboratory of Clinical Epidemiology

IRCCS Policlinico S. Matteo Foundation

Pavia

Italy

Declarações

GB declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Shakoory B, Geerlinks A, Wilejto M, et al. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Ann Rheum Dis. 2023 Oct;82(10):1271-85.Texto completo  Resumo

Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-58.Texto completo  Resumo

Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

O uso deste conteúdo está sujeito ao nosso aviso legal